Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022GlobeNewsWire • 06/17/22
Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a BetZacks Investment Research • 06/08/22
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022GlobeNewsWire • 05/31/22
Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?Zacks Investment Research • 05/23/22
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022GlobeNewsWire • 05/20/22
Altimmune, Inc. (ALT) CEO Vipin K. Garg on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in ObesityGlobeNewsWire • 04/01/22
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/15/22
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/15/22
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022GlobeNewsWire • 03/08/22
Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/17/22
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022GlobeNewsWire • 01/03/22
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21